Louise Baskin - Senior Product Manager, GE Healthcare
Yorba Linda, CA (PRWEB) May 31, 2016
Interest is on the rise for using the CRISPR-Cas9 system for functional screening, as both a primary screening tool and as an orthogonal tool for RNAi hit validation. A key reason may be that high-throughput synthesis—combined with a proprietary algorithm that selects highly functional and specific guide RNAs—allows rapid generation of CRISPR RNA (crRNA) collections in arrayed formats.
Arrayed crRNA screens have the advantage of applying sophisticated assays, such as those requiring high-content microscopy, to investigate phenotypes that involve intracellular localization, morphological changes, or require time-lapse investigation. Pooled lentiviral sgRNA screens have proven useful for loss-of-function studies, however, the types of assays used are typically limited to viability, sensitization, and some reporter assays.
GE Healthcare is sponsoring a new, free educational webinar, “A workflow for CRISPR-Cas9 high throughput arrayed screening with synthetic crRNA,” which will discuss the application of arrayed screening with synthetic crRNA libraries across multiple assay types, and present considerations for experimental success. Topics include key elements in successful arrayed crRNA screening, benefits of the two-partCRISPR guide RNA approach, guidelines for optimizing reverse transfection with crRNA and tracrRNA, recommendations for Cas9 nuclease selection in screening applications, and supporting products and resources. Continuing education credits will be offered through the PACE system.
The speaker is Louise Baskin, MS, senior product manager, GE Healthcare. Baskin, who joined Dharmacon RNA Technologies in 2005, has led the development and commercial launch of multiple genome-wide siRNA and microRNA product lines. She is also responsible for developing and expanding the Dharmacon™ Edit-R™ Genome Engineering portfolio, which includes synthetic crRNA and lentiviral sgRNA, in addition to Cas9 nucleases in inducible or constitutive lentiviral vectors, DNA plasmid mRNA, or protein formats. She works closely with a respected team of R&D scientists on innovative CRISPR-Cas9 tools and services. Baskin earned a master’s degree in molecular biology and genetics at Northwestern University.
The free webinar, hosted by LabRoots, will be presented on June 23, 2016, at 8 am Pacific Time/11 am Eastern Time.
For full details about the event, obtaining continuing education credits, and free registration, click here.
About Dharmacon:
Dharmacon, part of GE Healthcare, has revolutionized the field of RNA synthesis with the introduction of 2’-ACE synthesis chemistry. As a leader in custom RNA synthesis, Dharmacon was an early participant in the newly discovered field of RNA interference, and contributed several key scientific findings. Dharmacon RNAi products were some of the first commercially available. This leadership has continued through technical advances in bioinformatics, and chemical modifications to improve performance. The company’s areas of research and research tools have expanded to support all aspects of RNAi interference; siRNA, lentiviral shRNA, tools for microRNA research, and whole-genome scale libraries for RNAi functional screens of genes, microRNAs, and long non-coding RNAs. Dharmacon has the largest collection of cDNAs and ORFs commercially available, and a unique set of synthetic CRISPR-Cas9 gene editing tools.
About LabRoots:
LabRoots is the leading scientific social networking website and producer of educational virtual events and webinars. Contributing to the advancement of science through content sharing capabilities, LabRoots is a powerful advocate in amplifying global networks and communities. Founded in 2008, LabRoots emphasizes digital innovation in scientific collaboration and learning, and is a primary source for current scientific news, webinars, virtual conferences, and more. LabRoots has grown into the world’s largest series of virtual events within the Life Sciences and Clinical Diagnostics community.